Identification of CLP36 as a Tumor Antigen that Induces an Antibody Response in Pancreatic Cancer

다국어 초록 (Multilingual Abstract)

Purpose: Pancreatic cancer has a poor prognosis, due in part to the lack of an effective approach for its early detection. The identification of tumor antigens potentially provides a means for the early diagnosis. The purpose of this study was to use a proteomic approach for the identification of proteins that commonly induce a humoral response in patients with pancreatic cancer. Materials and Methods: Proteins from the pancreatic adenocarcinoma cell line, BxPC3, were subjected to two- dimensional polyacrylamide gel electrophoresis, followed by Western blot analysis, where individual sera were tested for autoantibodies. Sera from 36 patients with pancreatic adenocarcinoma, and 68 from control groups (14 from lung adenocarcinoma, 19 from colon adenocarcinoma and 35 from healthy subjects) were analyzed. CLP36 expression was evaluated by immunohistochemical analysis and real- time PCR. The cellular localization of CLP36 as an autoantigen was investigated by Western blot analysis. Results: The autoantibody was detected against a protein, identified by mass spectrometry as CLP36, in 14 of the 36 sera (38.9%) from patients with a pancreatic adenocarcinoma, and 3 of the 68 controls (4.4%). Immunohistochemical analysis of CLP36 in a tissue array demonstrated diffuse and consistent immunoreactivity in the pancreatic adenocarcinomas. The levels of CLP36 mRNA were highest in the pancreatic cancer cell lines of the different cells analyzed. The molecular weight of the protein displayed in the membrane-rich fraction was larger than that in the cytosolic fraction, which is likely attributable to a post-translational modification. Conclusion: CLP36 was identified as a tumor autoantigen inducing a humoral immune response in pancreatic adenocarcinomas. More detailed studies need to be undertaken to understand whether the humoral response by CLP36 is tumor-specific.

참고문헌 (Reference)

1 "p53 autoantibodies in patients with pancreatitis andpancreatic carcinoma" 13 : 241-6, 1996

2 "Tissue microarrays for high-throughputmolecular profiling of tumor specimens" 4 : 844-7, 1998

3 "TheLIM/double zinc-finger motif functions as a protein dimerizationdomain" 91 : 10655-9, 1994

4 "Proteomics-based identification of RS/DJ-1 asa novel circulating tumor antigen in breast cancer" 7 : 3328-35, 2001

5 "Protein-protein interaction of zinc finger LIMdomains with protein kinase C" 271 : 31029-32, 1996

6 "Posttranslational protein modifications:new flavors in the menu of autoantigens" 14 : 244-9, 2002

7 "Mass spectrometric identification of proteins from silverstainedpolyacrylamide gel a method for the removal of silverions to enhance sensitivity" 601-5, 1999

8 "LIM domains: multiple rolesas adapters and functional modifiers in protein interactions" 14 : 156-62, 1998

9 "LIM domain proteins" 318 : 295-306, 1995

10 "Intracellulardistribution of the La antigen in CV-1 cells after herpes simplexvirus type 1 infection compared with the localization ofU small nuclear ribonucleoprotein particles" 881-4 91, 1989

11 "Harnessing immunity for cancer marker discovery" 21 : 37-8, 2003

12 "Development of antibodies against p53 in lungcancer patients appears to be dependent on the type of p53mutation" 52 : 4168-74, 1992

13 "Circulating antibodies against c-myc oncogeneproduct in sera of colorectal cancer patients" 46 : 35-8, 1990

14 "CLP-36 PDZ-LIM proteinassociates with nonmuscle alpha-actinin-1 and alpha-actinin-4" 275 : 11100-5, 2000

15 "Autoimmune hepatitis associated with antiactinantibodies in children and adolescents" 17 : 376-81, 1993

16 "Autoantigens as substrates forapoptotic proteases:implications for the pathogenesis ofsystemic autoimmune disease" 6 : 6-12, 1999

17 "Autoantibodies in theserum of patients with gastric cancer:their prognostic importance" 17 : 431-5, 1998

18 "Autoantibodies in sera of pancreatic cancerpatients identify recombination factor Rad51 as a tumourassociatedantigen" 128 : 219-22, 2002

19 "Antibodyresponse against the c-erbB-2 oncoprotein in breast carcinomapatients" 53 : 5864-6, 1993

20 "Anti-actin antibodies in sera from patients with autoimmuneliver diseases and patients with carcinomas by ELISA" 48 : 129-32, 1995

21 "An immune response manifested by the commonoccurrence of annexins I and II autoantibodies and highcirculating levels of IL-6 in lung cancer" 98 : 9824-9, 2001

22 "Advances in two-dimensional electrophoresis" 337 : 485-6, 1989

23 "Actinin-4, a novel actin-bundling protein associated withcell motility and cancer invasion." 140 : 1383-93, 1998

24 "A survey of the humoral immune response of cancerpatients to a panel of human tumor antigens" 187 : 1349-54, 1998

25 "A point mutation in thealpha-actinin-4 gene generates an antigenic peptide recognizedby autologous cytolytic T lymphocytes on a human lungcarcinoma" 61 : 4078-83, 2001